Taiwan · Delayed Price · Currency is TWD HanchorBio Company Description
HanchorBio Inc. engages in the research and development of new anti-cancer drugs in Hong Kong and Mainland China.
The companys product pipeline consists of HCB101, which is in phase II clinical trial to treat head and neck cancer, triple-negative breast cancer, gastric cancer, colorectal cancer, and small cell lung cancer; HCB301, which is in phase I clinical trial for the treatment of hematologic malignancies, head and neck cancer, and solid tumors; and HCB303, which is in preclinical trial to treat hematologic malignancies, head and neck cancer, and solid tumors.
Its technology is the Fc-Based Designer Biologics platform, which focuses on the development of next-generation immuno-oncology fusion protein therapeutic.
HanchorBio Inc. was founded in 2008 and is based in Taipei, Taiwan.
| Country | Cayman Islands |
| Founded | 2008 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 127 |
| CEO | Shi-Kau Liu |
Contact Details
Address: No. 1, Tiding Blvd Taipei, 114 Taiwan | |
| Phone | 886 2 2792 1366 |
| Website | hanchorbio.com |
Stock Details
| Ticker Symbol | 7827 |
| Exchange | Taiwan Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | KYG4277B1068 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Shi-Kau Liu | Chief Executive Officer |